Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke

  • Hok-Hay S. Oei
    From the Departments of Epidemiology and Biostatistics (H.-H.S.O., I.M.v.d.M., A.H., T.S., M.M.B.B., J.C.M.W.) and Neurology (P.J.K.), Erasmus Medical Center, Rotterdam, the Netherlands.
  • Irene M. van der Meer
    From the Departments of Epidemiology and Biostatistics (H.-H.S.O., I.M.v.d.M., A.H., T.S., M.M.B.B., J.C.M.W.) and Neurology (P.J.K.), Erasmus Medical Center, Rotterdam, the Netherlands.
  • Albert Hofman
    From the Departments of Epidemiology and Biostatistics (H.-H.S.O., I.M.v.d.M., A.H., T.S., M.M.B.B., J.C.M.W.) and Neurology (P.J.K.), Erasmus Medical Center, Rotterdam, the Netherlands.
  • Peter J. Koudstaal
    From the Departments of Epidemiology and Biostatistics (H.-H.S.O., I.M.v.d.M., A.H., T.S., M.M.B.B., J.C.M.W.) and Neurology (P.J.K.), Erasmus Medical Center, Rotterdam, the Netherlands.
  • Theo Stijnen
    From the Departments of Epidemiology and Biostatistics (H.-H.S.O., I.M.v.d.M., A.H., T.S., M.M.B.B., J.C.M.W.) and Neurology (P.J.K.), Erasmus Medical Center, Rotterdam, the Netherlands.
  • Monique M.B. Breteler
    From the Departments of Epidemiology and Biostatistics (H.-H.S.O., I.M.v.d.M., A.H., T.S., M.M.B.B., J.C.M.W.) and Neurology (P.J.K.), Erasmus Medical Center, Rotterdam, the Netherlands.
  • Jacqueline C.M. Witteman
    From the Departments of Epidemiology and Biostatistics (H.-H.S.O., I.M.v.d.M., A.H., T.S., M.M.B.B., J.C.M.W.) and Neurology (P.J.K.), Erasmus Medical Center, Rotterdam, the Netherlands.

Bibliographic Information

Other Title
  • The Rotterdam Study

Description

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been proposed as an inflammatory marker of cardiovascular disease. In the present study, we investigated whether Lp-PLA2 is an independent predictor of coronary heart disease and ischemic stroke. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> The Rotterdam Study is a population-based follow-up study in 7983 subjects ≥55 years of age. We performed a case-cohort study, including 308 coronary heart disease cases, 110 ischemic stroke cases, and a random sample of 1820 subjects. We used Cox proportional-hazard models with modification of the standard errors based on robust variance estimates to compute hazard ratios adjusted for age, sex, body mass index, systolic blood pressure, non-HDL cholesterol, HDL cholesterol, diabetes, smoking, alcohol consumption, cholesterol-lowering medication, white blood cell count, and C-reactive protein. Compared with the first quartile of Lp-PLA2 activity, multivariate-adjusted hazard ratios for coronary heart disease for the second, third, and fourth quartiles were 1.39 (95% CI, 0.92 to 2.10), 1.99 (95% CI, 1.32 to 3.00), and 1.97 (95% CI, 1.28 to 3.02), respectively ( <jats:italic>P</jats:italic> for trend=0.01). Corresponding multivariate-adjusted hazard ratios for ischemic stroke were 1.08 (95% CI, 0.55 to 2.11), 1.58 (95% CI, 0.82 to 3.04), and 1.97 (95% CI, 1.03 to 3.79) ( <jats:italic>P</jats:italic> for trend=0.03). The relation between Lp-PLA2 and coronary heart disease was present in both subjects with non-HDL cholesterol levels below the median and those with non-HDL cholesterol levels above the median. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> This study shows that Lp-PLA2 activity is an independent predictor of coronary heart disease and ischemic stroke in the general population. </jats:p>

Journal

  • Circulation

    Circulation 111 (5), 570-575, 2005-02-08

    Ovid Technologies (Wolters Kluwer Health)

Citations (4)*help

See more

Details 詳細情報について

Report a problem

Back to top